HWHG(SH:600079) Xin Lang Cai Jing·2025-12-19 03:56Core Viewpoint - Recently, the Shanghai Stock Exchange listed company Renfu Pharmaceutical (600079.SH) announced that it is facing administrative penalties from the Hubei Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose non-operating fund occupation by its controlling shareholder, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022, along with significant omissions and false records in periodic reports. The regulatory bureau intends to issue a warning and impose a total fine of 8.5 million yuan on the company [2][27]. Group 1 - Renfu Pharmaceutical failed to timely disclose non-operating fund occupation, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022 [6][32]. - The company’s 2020 annual report omitted the disclosure of 2.502 billion yuan of non-operating fund occupation, which accounted for 19.26% of the net assets recorded in the report [9][35]. - In 2021, the company reported a cumulative non-operating fund occupation of 8.179 billion yuan, representing 62.97% of the net assets [8][34]. Group 2 - The company did not disclose significant related party transactions in its 2022 annual report, including a total of 1.645 billion yuan in property asset purchases from a related party, which accounted for 9.17% of the net assets [11][37]. - Renfu Pharmaceutical's 2020, 2021, and 2022 semi-annual reports contained false records, leading to inflated net profits of 143 million yuan, 72 million yuan, and 91 million yuan respectively [12][38]. Group 3 - The controlling shareholder, Wuhan Contemporary Technology Industry Group, directed Renfu Pharmaceutical to provide funds for its own needs, constituting non-operating fund occupation [18][19]. - The regulatory bureau proposed fines totaling 8.5 million yuan against Renfu Pharmaceutical and its executives for the violations, including a 3.5 million yuan fine for the company itself [19][21].